male and female subjects, 18-65 years of age (females non-child bearing potential in part b)

have laboratory evidence of hcv infection for 6 months, defined by (1) presence of anti-hcv antibody (genotype 1a and 1b infection), or (2)documented hcv rna presence by a sensitive and specific assay and (3 histologic evidence of chc (fibrosis on a standardized histological grading system)

plasma hcv rna of 100,000 iu/ml

hiv 1 and hiv2 ab seronegative

body mass index (bmi) ≤ 35 kg/m2 bmi

treatment naive subjects

contraindications to peginterferon or ribavirin therapy

have evidence of liver cirrhosis, decompensated liver disease, and child-pugh score > 5

have hemoglobinopathies, unstable cardiac disease, history of organ transplant, active malignant disease or uncontrolled type i or ii diabetes